Jump to content

Publication: Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer

From CAMIH
Revision as of 09:44, 21 August 2024 by EProba (talk | contribs) (Created page with "{{Publication |Title=Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer |Topic=Enzymes (bromelain papain) |Author=Kasseroller, R; Wenning, HG |Year=2003 |Journal=The European Journal of Lymphology and related problem |DOI=- |Authors Abstract=Aim of the study was to investigate the influence of a proteolytic enzyme, the drug Wobenzym, (Mucos Emulsionsges. mbH, Wien. Austria), on the...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


Reference
Title Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer
Topic Enzymes (bromelain papain)
Author Kasseroller, R, Wenning, HG
Year 2003
Journal The European Journal of Lymphology and related problem
DOI -

Author's Abstract The abstract and the information and conclusions contained therein were written by the authors of the publication.

Aim of the study was to investigate the influence of a proteolytic enzyme, the drug Wobenzym, (Mucos Emulsionsges. mbH, Wien. Austria), on the volume of the lmyphoedema in the limb and the fibrotic changes in the tissue in secondary lymphoedema patients after axillary lymph node dissection due to mammary cancer who received combined decongestive physical treatment (CDT).



This publication is referenced in the following studies:

  1. Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer